A 16-Histidine Peptide Turns Liposomes into Lysosome-Targeting Drug Carriers

Researchers prepared liposomes modified with a stearyl-H16 peptide (the fatty acid anchor inserts into the liposome membrane). They tested cellular uptake in human fibrosarcoma cells, identified the endocytosis pathways involved, tracked intracellular localization, and then loaded the liposomes with GLA enzyme to test functional delivery to lysosomes in GLA-deficient cells.

Lysosomal storage diseases (LSDs) are a group of ~50 rare genetic disorders caused by missing lysosomal enzymes, affecting roughly 1 in 5,000 births. Current enzyme replacement therapies often struggle to get enzymes inside cells and specifically into lysosomes. A peptide-modified liposome that naturally targets lysosomes could dramatically improve drug delivery for these devastating conditions.

Cell-penetrating peptides are one of the hottest areas in drug delivery research because they solve the fundamental problem of getting large molecules through cell membranes. This study adds a new dimension by showing that a specific CPP doesn't just get cargo inside cells — it delivers it to a specific organelle (lysosomes). This kind of subcellular targeting could transform treatment for the ~50 known lysosomal storage diseases and potentially other conditions requiring intracellular drug delivery.

This is an in vitro study using a single cancer cell line (fibrosarcoma), which may not reflect uptake in normal human cells or in vivo conditions. No animal studies were conducted. The abstract doesn't report quantitative uptake efficiency, GLA activity restoration levels, or comparison with existing enzyme replacement delivery methods. Long-term stability and immunogenicity of H16-Lipo were not assessed.